ATE431827T1 - Phosphonocephem-verbindung - Google Patents

Phosphonocephem-verbindung

Info

Publication number
ATE431827T1
ATE431827T1 AT01955659T AT01955659T ATE431827T1 AT E431827 T1 ATE431827 T1 AT E431827T1 AT 01955659 T AT01955659 T AT 01955659T AT 01955659 T AT01955659 T AT 01955659T AT E431827 T1 ATE431827 T1 AT E431827T1
Authority
AT
Austria
Prior art keywords
compound
phosphonocephem
phosphonocephem compound
formula
compound represented
Prior art date
Application number
AT01955659T
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Shohei Hashiguchi
Yuji Iizawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26598061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE431827(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE431827T1 publication Critical patent/ATE431827T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65613Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. cephalosporins and analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT01955659T 2000-08-10 2001-08-10 Phosphonocephem-verbindung ATE431827T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000247966 2000-08-10
JP2000354959 2000-11-21
PCT/JP2001/006904 WO2002014333A1 (en) 2000-08-10 2001-08-10 Phosphonocephem compound

Publications (1)

Publication Number Publication Date
ATE431827T1 true ATE431827T1 (de) 2009-06-15

Family

ID=26598061

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01955659T ATE431827T1 (de) 2000-08-10 2001-08-10 Phosphonocephem-verbindung

Country Status (13)

Country Link
US (2) US6906055B2 (de)
EP (2) EP2020416A1 (de)
KR (1) KR100826487B1 (de)
CN (1) CN1189471C (de)
AT (1) ATE431827T1 (de)
AU (1) AU2001277753A1 (de)
CA (1) CA2418614C (de)
CY (1) CY1109313T1 (de)
DE (1) DE60138760D1 (de)
DK (1) DK1310502T3 (de)
ES (1) ES2323759T3 (de)
PT (1) PT1310502E (de)
WO (1) WO2002014333A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020416A1 (de) * 2000-08-10 2009-02-04 Takeda Pharmaceutical Company Limited Phosphonocephem-Verbindung
AT501931B1 (de) * 2004-12-10 2007-08-15 Chemiefaser Lenzing Ag Cellulosestapelfaser und ihre verwendung
US20070238719A1 (en) * 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US20070238720A1 (en) * 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
WO2009039324A1 (en) * 2007-09-21 2009-03-26 Forest Laboratories Holdings Limited Soluble dosage forms containing cephem derivatives suitable for parenteral administration
BRPI0916885B8 (pt) * 2008-08-28 2021-05-25 Astrazeneca Ab composição farmacêutica
US8247400B2 (en) * 2009-02-23 2012-08-21 Dedhiya Mahendra G Cephem compounds useful for the treatment of bacterial infections
MX2012003201A (es) * 2009-09-21 2012-05-08 Astrazeneca Ab Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
BR112013032415B1 (pt) 2011-06-17 2021-07-27 Pfizer Anti-Infectives Ab Processos para preparar compostos e compostos
WO2013034718A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Novel process for preparing ceftaroline fosamil
WO2013084171A1 (en) 2011-12-07 2013-06-13 Ranbaxy Laboratories Limited Process for preparing ceftaroline salts or hydrates thereof
AU2013331880B2 (en) * 2012-10-19 2018-08-09 Sandoz Ag Novel process for preparing ceftaroline fosamil
CN102977124B (zh) * 2012-12-13 2014-11-26 山东诚创医药技术开发有限公司 7β-[(苯乙酰)氨基]-3-[4-(1-甲基-4-吡啶鎓)-2-噻唑硫基]-3-头孢烯-4-羧酸二苯甲基酯的制备方法
US9534004B2 (en) * 2012-12-20 2017-01-03 Sandoz Ag Crystalline forms of ceftaroline fosamil
WO2015127316A1 (en) 2014-02-21 2015-08-27 Micurx Pharmaceuticals, Inc. Water-soluble o-carbonyl phosphoramidate prodrugs for therapeutic administration
WO2016008393A1 (zh) * 2014-07-14 2016-01-21 正大天晴药业集团股份有限公司 头孢罗膦氨基酸盐及其结晶
CN104177408B (zh) * 2014-09-12 2016-09-07 衡水衡林生物科技有限公司 (z)-2-(5-二氯磷酰氨基-1,2,4-噻二唑-3-基)-2-乙氧亚胺基乙酰氯的制备方法
WO2016066631A1 (en) 2014-10-28 2016-05-06 Sandoz Ag Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution
WO2016128580A1 (en) * 2015-02-13 2016-08-18 Fresenius Kabi Anti-Infectives Srl Cephalosporin intermediate and process for its preparation
CN104725425B (zh) * 2015-04-09 2017-01-04 山东罗欣药业集团股份有限公司 一种头孢洛林酯的制备方法
CN104892674B (zh) * 2015-06-18 2017-01-18 河北大学 一种头孢洛林酯的制备方法
CN107216353B (zh) * 2016-03-21 2020-05-19 山东诚创医药技术开发有限公司 一种头孢洛林酯咪唑盐的精制方法
CN106565784B (zh) * 2016-10-31 2019-02-26 瑞阳制药有限公司 头孢洛林酯二钠盐的纯化方法
CN106749410B (zh) * 2016-12-02 2018-06-12 齐鲁安替制药有限公司 一种高收率头孢洛林酯的制备方法
CN107325114B (zh) * 2017-07-04 2019-06-11 吉林省爱诺德生物工程有限公司 一种头孢洛林酯中间体的制备方法
CN108440566A (zh) * 2018-01-04 2018-08-24 北京满格医药科技有限公司 一种头孢洛林酯中间体1的精制方法
CN110872322B (zh) * 2018-08-29 2022-08-02 上海博志研新药物技术有限公司 乙酸头孢罗膦一水合物及其中间体的制备方法
KR102205496B1 (ko) * 2019-02-27 2021-01-21 국제약품(주) 세팔로스포린 화합물 제조용 중간체의 제조방법 및 그로부터 제조된 세프타롤린 포사밀 금속염
CN113214323A (zh) * 2021-04-30 2021-08-06 瑞阳制药股份有限公司 分段式头孢罗膦高效稳定析晶方法
CN113336775A (zh) * 2021-06-21 2021-09-03 湖北凌晟药业有限公司 一种头孢维星中间体的合成方法
CN115417886B (zh) * 2022-09-19 2024-06-14 瑞阳制药股份有限公司 头孢类医药中间体的高效制备方法
CN120098038A (zh) * 2025-05-07 2025-06-06 广东立国制药有限公司 一种头孢洛林酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4142059A (en) * 1976-04-02 1979-02-27 Eli Lilly And Company Spray drying sodium and potassium 2-ethylhexanoate
EP0828744A1 (de) * 1995-05-29 1998-03-18 Takeda Chemical Industries, Ltd. Cephemverbindungen, ihre herstellung und anwendung
JP3927262B2 (ja) 1995-07-19 2007-06-06 武田薬品工業株式会社 セフェム化合物、その製造法および抗菌組成物
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
JP2000247966A (ja) 1999-03-01 2000-09-12 Wakunaga Pharmaceut Co Ltd 2,6−ジアルキル−γ―ピロン誘導体の製造法及びその製造中間体
US6050882A (en) 1999-06-10 2000-04-18 Applied Materials, Inc. Carrier head to apply pressure to and retain a substrate
EP2020416A1 (de) * 2000-08-10 2009-02-04 Takeda Pharmaceutical Company Limited Phosphonocephem-Verbindung

Also Published As

Publication number Publication date
KR20030022891A (ko) 2003-03-17
EP1310502B1 (de) 2009-05-20
EP1310502A4 (de) 2007-08-01
WO2002014333A1 (en) 2002-02-21
EP2020416A1 (de) 2009-02-04
DE60138760D1 (de) 2009-07-02
ES2323759T3 (es) 2009-07-24
KR100826487B1 (ko) 2008-05-02
US7419973B2 (en) 2008-09-02
DK1310502T3 (da) 2009-09-07
CN1462275A (zh) 2003-12-17
CN1189471C (zh) 2005-02-16
CY1109313T1 (el) 2014-07-02
PT1310502E (pt) 2009-07-31
CA2418614C (en) 2008-06-10
US6906055B2 (en) 2005-06-14
CA2418614A1 (en) 2003-02-04
US20050176697A1 (en) 2005-08-11
EP1310502A1 (de) 2003-05-14
AU2001277753A1 (en) 2002-02-25
US20040023943A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
ATE431827T1 (de) Phosphonocephem-verbindung
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
DE60229736D1 (de) Spiroinden- und spiroindan-verbindungen
CY1114008T1 (el) Θειενοπυριμιδινικες ενωσεις και χρηση τους
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
SE0000540D0 (sv) New compounds
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
DE60335359D1 (de) Phthalazinonderivate
SE0100902D0 (sv) Compounds
ATE404528T1 (de) 7,9 substituierte tetracyclinverbindungen
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
NO20014925L (no) Farmasöytiske forbindelser
DE69426602D1 (de) 2,3-diaminopropionsäurederivate
CR6574A (es) Sales de avermectinas substituidas en la posicion 4 con propiedades plaguicidas
IS5497A (is) Bífenýlamidínafleiður
DOP2002000371A (es) Fenil-heterociclil-eteres
IL154014A0 (en) Process for the preparation of 2-aminoethylpyridines
PT1255745E (pt) Sintese de derivados de agua soluvel 9-dihidro-paclitaxelo de 9-dihidro-13-acetilobacatina iii
DE60039695D1 (de) Antifucoidan antikörper
DK1085019T3 (da) Omoprazolsyntese
HN1999000038A (es) Nuevos compuestos fungicidas
EP1557407A4 (de) Neue alpha-ketoamidderivate und deren verwendung
DK0645374T3 (da) 5-Amino-2-phenoxylsulfonanilidforbindelse
UY26778A1 (es) Derivados de ácido heteroarilalcanoico.
DE60230924D1 (de) 2-substituierte vitamin-d-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1310502

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1310502

Country of ref document: EP